1. Home
  2. AGD vs LUNG Comparison

AGD vs LUNG Comparison

Compare AGD & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Global Dynamic Dividend Fund of Beneficial Interest

AGD

abrdn Global Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$12.18

Market Cap

318.4M

Sector

Finance

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.27

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGD
LUNG
Founded
N/A
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Industrial Specialties
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.4M
57.9M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
AGD
LUNG
Price
$12.18
$1.27
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
104.8K
523.3K
Earning Date
01-01-0001
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$10.13
$1.13
52 Week High
$13.98
$3.88

Technical Indicators

Market Signals
Indicator
AGD
LUNG
Relative Strength Index (RSI) 49.04 45.03
Support Level $11.20 $1.27
Resistance Level $12.31 $1.45
Average True Range (ATR) 0.20 0.09
MACD -0.02 0.01
Stochastic Oscillator 15.15 35.19

Price Performance

Historical Comparison
AGD
LUNG

About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest

Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: